Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK The House Committee on Government Reform has accused the Food and Drug Administration of being slow to enforce regulations prohibiting false or misleading advertising by pharmaceutical companies.
The committee did so in a Feb. 29 report prepared at the request of Rep. Henry Waxman of California, the ranking Democrat on the committee.
According to the report, enforcement actions by the FDA fell 75 percent in 2003, compared with the “last years of the Clinton administration.”
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in